Compounders Research Compare

Rezolute, Inc.(RZLT)

Biotechnology · Redwood City, CA

$4.28-0.05 (-1.27%)

Delayed quote: Oct 6, 2026, 1:15 PM EDT

About Rezolute, Inc.

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Redwood City, CA

58 employees

www.rezolutebio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Nevan Charles Elam

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T17:18:03.602Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:18:03.602Z.

Quote observation: 2026-10-06T17:15:11.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 411,649,583
Total debt · period ending 2026-06-30: 934,000
Cash · period ending 2026-06-30: 10,615,000
TTM operating EBITDA · period ending 2026-06-30: -82,935,000

FMP input reference: eb6c183c54b52a3f5be7b88cd35f52a8db6123751fb387d2cb2c86d403628cdc

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

RZLT EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

RZLT Competitors' EV/EBITDA Ratio

Rezolute, Inc.

Current

Market Cap

$411.65M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Prothena Corporation plc

Market Cap

$411.76M

EV/EBITDA Ratio

N/A

TTM Avg

16.39x

3Y Avg

16.39x

5Y Avg

16.39x

Strata Critical Medical, Inc.

Market Cap

$410.19M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Shoulder Innovations, Inc.

Market Cap

$409.99M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Atea Pharmaceuticals, Inc.

Market Cap

$407.34M

EV/EBITDA Ratio

N/A

TTM Avg

5.73x

3Y Avg

28.73x

5Y Avg

28.73x

Eikon Therapeutics, Inc. Common Stock

Market Cap

$403.87M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Myriad Genetics, Inc.

Market Cap

$413.54M

EV/EBITDA Ratio

N/A

TTM Avg

30.26x

3Y Avg

22.88x

5Y Avg

18.64x

Neurogene Inc.

Market Cap

$406.04M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Carlsmed, Inc.

Market Cap

$406.41M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Senseonics Holdings, Inc.

Market Cap

$419.42M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Rezolute, Inc. (RZLT)	$411.65M	N/A	N/A	N/A	N/A
Prothena Corporation plc (PRTA)vs ›	$411.76M	N/A	16.39x	16.39x	16.39x
Strata Critical Medical, Inc. (SRTA)vs ›	$410.19M	N/A	N/A	N/A	N/A
Shoulder Innovations, Inc. (SI)vs ›	$409.99M	N/A	N/A	N/A	N/A
Atea Pharmaceuticals, Inc. (AVIR)vs ›	$407.34M	N/A	5.73x	28.73x	28.73x
Eikon Therapeutics, Inc. Common Stock (EIKN)vs ›	$403.87M	N/A	N/A	N/A	N/A
Myriad Genetics, Inc. (MYGN)vs ›	$413.54M	N/A	30.26x	22.88x	18.64x
Neurogene Inc. (NGNE)vs ›	$406.04M	N/A	N/A	N/A	N/A
Carlsmed, Inc. (CARL)vs ›	$406.41M	N/A	N/A	N/A	N/A
Senseonics Holdings, Inc. (SENS)vs ›	$419.42M	N/A	N/A	N/A	N/A

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics